Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCE
  • CUSIP: N/A
  • Web: www.sparktx.com
Capitalization:
  • Market Cap: $2.26 billion
  • Outstanding Shares: 31,128,000
Average Prices:
  • 50 Day Moving Avg: $60.23
  • 200 Day Moving Avg: $58.19
  • 52 Week Range: $35.07 - $74.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.63
  • P/E Growth: -0.56
Sales & Book Value:
  • Annual Revenue: $20.17 million
  • Price / Sales: 112.17
  • Book Value: $9.32 per share
  • Price / Book: 7.80
Profitability:
  • EBIDTA: ($137,080,000.00)
  • Net Margins: -745.48%
  • Return on Equity: -44.06%
  • Return on Assets: -39.34%
Debt:
  • Current Ratio: 8.86%
  • Quick Ratio: 8.86%
Misc:
  • Average Volume: 338,449 shs.
  • Beta: 3.36
  • Short Ratio: 12.48
 
Frequently Asked Questions for Spark Therapeutics (NASDAQ:ONCE)

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics, Inc. (NASDAQ:ONCE) announced its earnings results on Tuesday, May, 9th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.36) by $0.34. The company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.35 million. Spark Therapeutics had a negative net margin of 745.48% and a negative return on equity of 44.06%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.95) earnings per share. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

10 brokers have issued 12-month target prices for Spark Therapeutics' stock. Their predictions range from $28.00 to $94.00. On average, they anticipate Spark Therapeutics' stock price to reach $71.28 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

What are analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. Chardan Capital analysts commented, "We continue to expect ENDP shares to be range-bound in the near to medium term. Our recent analysis of ENDP’s additional unfunded mesh liability and discussion with a legal expert familiar with mass tort/product liability defense ligation supports our view ENDP will remain highly levered (in the 4s) and the company’s turnaround will take several years. While we view any of our potential settlement scenarios for the company’s additional unfunded mesh liability to be manageable, we believe continued pricing pressure in ENDP’s US generics base business, need for additional advertising and promotion spend to support Xiaflex growth and inability to grow through meaningful acquisitions leave ENDP little room for error." (7/24/2017)
  • 2. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (7/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
  • 4. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board
  • Katherine A. High M.D., President, Chief Scientific Officer, Director
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
  • Stephen W. Webster, Chief Financial Officer
  • John Furey, Chief Operating Officer
  • Joseph W. La Barge Esq., General Counsel
  • Daniel R. Faga, Chief Business Officer
  • Lars G. Ekman M.D. Ph.D., Independent Director
  • Anand Mehra M.D., Independent Director
  • Vincent J. Milano, Independent Director

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include TYPENEX COMPANY -INVESTMENT, LLC (9.99%), Sofinnova Management VIII L.L.C. (2.23%), Russell Investments Group Ltd. (0.08%) and Fox Run Management L.L.C. (0.03%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Sofinnova Management VIII L.L.C.. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $72.68.


MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $71.28 (1.93% downside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/24/2017Jefferies Group LLCReiterated RatingBuy$85.00HighView Rating Details
7/24/2017Chardan CapitalReiterated RatingHold -> NeutralHighView Rating Details
7/17/2017Cantor FitzgeraldSet Price TargetBuy$94.00MediumView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
5/10/2017WedbushReiterated RatingUnderperform$28.00MediumView Rating Details
4/10/2017Stifel NicolausReiterated RatingBuy$76.00LowView Rating Details
4/7/2017BMO Capital MarketsReiterated RatingOutperform$69.00LowView Rating Details
2/22/2017Cowen and CompanySet Price TargetBuy$75.00N/AView Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00N/AView Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00N/AView Rating Details
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$70.00N/AView Rating Details
6/21/2016SunTrust Banks, Inc.Boost Price TargetBuy$64.00 -> $72.00N/AView Rating Details
4/12/2016Evercore ISIInitiated CoverageBuy$37.00N/AView Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageBuy -> Neutral$44.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
10/11/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Spark Therapeutics (NASDAQ:ONCE)
Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Earnings History by Quarter for Spark Therapeutics (NASDAQ ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
2017 EPS Consensus Estimate: ($6.58)
2018 EPS Consensus Estimate: ($5.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20175($1.77)($1.71)($1.73)
Q3 20175($1.80)($1.73)($1.76)
Q4 20175($1.79)($1.18)($1.64)
Q1 20181($1.67)($1.67)($1.67)
Q2 20181($1.43)($1.43)($1.43)
Q3 20181($1.40)($1.40)($1.40)
Q4 20181($1.36)($1.36)($1.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 88.94%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.00View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.00View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.00View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.00View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Spark Therapeutics (NASDAQ:ONCE)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
Source:
DateHeadline
americanbankingnews.com logoSpark Therapeutics, Inc. (NASDAQ:ONCE) Insider Sells $210,000.00 in Stock
www.americanbankingnews.com - July 26 at 8:22 PM
americanbankingnews.com logoKatherine A. High Sells 10,000 Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) Stock
www.americanbankingnews.com - July 26 at 7:58 PM
americanbankingnews.com logoInsider Selling: Spark Therapeutics, Inc. (ONCE) Director Sells 211,858 Shares of Stock
www.americanbankingnews.com - July 26 at 7:16 PM
americanbankingnews.com logoChardan Capital Reiterates Neutral Rating for Spark Therapeutics, Inc. (ONCE)
www.americanbankingnews.com - July 24 at 10:06 AM
streetinsider.com logoSpark Therapeutics (ONCE) Receives FDA Rare Pediatric Disease ... - StreetInsider.com
www.streetinsider.com - July 21 at 5:37 AM
finance.yahoo.com logoSpark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
finance.yahoo.com - July 21 at 5:37 AM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - July 19 at 11:08 PM
americanbankingnews.com logo Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) Will Announce Earnings of -$1.75 Per Share
www.americanbankingnews.com - July 17 at 2:28 PM
bizjournals.com logoFDA accepts for priority review Spark Therapeutics' gene therapy for blindness
www.bizjournals.com - July 17 at 11:35 AM
finance.yahoo.com logoSpark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA
finance.yahoo.com - July 17 at 11:35 AM
americanbankingnews.com logoFinancial Analysis: Spark Therapeutics (ONCE) & Sucampo Pharmaceuticals (SCMP)
www.americanbankingnews.com - July 16 at 12:25 PM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 5:02 PM
finance.yahoo.com logoSpark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec
finance.yahoo.com - July 14 at 7:10 AM
americanbankingnews.com logoJefferies Group Weighs in on Spark Therapeutics, Inc.'s Q2 2017 Earnings (NASDAQ:ONCE)
www.americanbankingnews.com - July 13 at 8:29 AM
streetinsider.com logoSpark Therapeutics (ONCE) Presents Updated Interim Hemophilia B Data at ISTH - StreetInsider.com
www.streetinsider.com - July 12 at 6:36 AM
nasdaq.com logoImplied Volatility Surging for Spark Therapeutics (ONCE) Stock Options - Nasdaq
www.nasdaq.com - July 12 at 6:36 AM
finance.yahoo.com logoImplied Volatility Surging for Spark Therapeutics (ONCE) Stock Options
finance.yahoo.com - July 12 at 6:36 AM
finance.yahoo.com logoSpark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
finance.yahoo.com - July 11 at 6:20 AM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : July 10, 2017
finance.yahoo.com - July 11 at 6:20 AM
americanbankingnews.com logoJefferies Group LLC Begins Coverage on Spark Therapeutics, Inc. (NASDAQ:ONCE)
www.americanbankingnews.com - July 10 at 5:26 PM
americanbankingnews.com logoInsider Selling: Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Sells 5,669 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM
americanbankingnews.com logoSpark Therapeutics, Inc. Forecasted to Earn Q2 2017 Earnings of ($1.73) Per Share (ONCE)
www.americanbankingnews.com - June 30 at 8:43 AM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Insider Katherine A. High Sells 10,000 Shares
www.americanbankingnews.com - June 29 at 7:49 PM
americanbankingnews.com logoInsider Selling: Spark Therapeutics, Inc. (ONCE) Insider Sells 4,500 Shares of Stock
www.americanbankingnews.com - June 29 at 7:48 PM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Receives New Coverage from Analysts at William Blair
www.americanbankingnews.com - June 28 at 8:16 AM
americanbankingnews.com logoAnalyzing Pain Therapeutics (PTIE) and Spark Therapeutics (ONCE)
www.americanbankingnews.com - June 24 at 10:14 PM
americanbankingnews.com logo$1.32 Million in Sales Expected for Spark Therapeutics, Inc. (ONCE) This Quarter
www.americanbankingnews.com - June 23 at 4:02 PM
nasdaq.com logoSpark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and ... - Nasdaq
www.nasdaq.com - June 23 at 8:48 AM
finance.yahoo.com logoSpark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
finance.yahoo.com - June 23 at 8:48 AM
americanbankingnews.com logoJeffrey D. Marrazzo Sells 9,331 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 22 at 7:28 PM
americanbankingnews.com logoAnand Mehra Sells 6,302 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 22 at 7:26 PM
americanbankingnews.com logoBidaskClub Upgrades Spark Therapeutics, Inc. (ONCE) to Hold
www.americanbankingnews.com - June 22 at 6:43 PM
americanbankingnews.com logoKatherine A. High Sells 10,000 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 21 at 7:47 PM
americanbankingnews.com logoStephen W. Webster Sells 7,663 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 21 at 7:47 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) to Post -$1.75 EPS
www.americanbankingnews.com - June 21 at 10:18 AM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - June 20 at 11:40 PM
americanbankingnews.com logoSpark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 19 at 4:40 PM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 8:32 AM
finance.yahoo.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : June 9, 2017
finance.yahoo.com - June 9 at 7:16 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) General Counsel Sells $275,000.00 in Stock
www.americanbankingnews.com - June 8 at 7:28 PM
globenewswire.com logoSpark Therapeutics to Participate in Multiple Conferences in June - GlobeNewswire (press release)
globenewswire.com - June 1 at 8:46 AM
finance.yahoo.com logoSpark Therapeutics to Participate in Multiple Conferences in June
finance.yahoo.com - June 1 at 8:46 AM
finance.yahoo.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : May 29, 2017
finance.yahoo.com - May 29 at 8:36 AM
americanbankingnews.com logo$1.32 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - May 28 at 10:16 AM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.75 Per Share
www.americanbankingnews.com - May 26 at 7:37 AM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM
finance.yahoo.com logoSpark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 7:15 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 23 at 2:20 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 21 at 8:02 PM

Social

Chart

Spark Therapeutics (ONCE) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff